{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:20:55Z","timestamp":1780500055983,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009250","name":"National Institute for Social Care and Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CRUK\/14\/022"],"award-info":[{"award-number":["CRUK\/14\/022"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.eclinm.2023.102059","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T14:47:10Z","timestamp":1687790830000},"page":"102059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial"],"prefix":"10.1016","volume":"61","author":[{"given":"Somnath","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1206-8355","authenticated-orcid":false,"given":"Christopher N.","family":"Hurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3915-7243","authenticated-orcid":false,"given":"Richard","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gwynne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4513-4964","authenticated-orcid":false,"given":"Christopher M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Markham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette S.","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Radhakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajarshi","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Schoenbuchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1452-8813","authenticated-orcid":false,"given":"Emiliano","family":"Spezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6669-0628","authenticated-orcid":false,"given":"Maria","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.L.","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.eclinm.2023.102059_bib1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2468-1253(20)30007-8","article-title":"The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Collaborators","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102059_bib2","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1136\/gutjnl-2020-321600","article-title":"Global burden of oesophageal and gastric cancer by histology and subsite in 2018","volume":"69","author":"Arnold","year":"2020","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102059_bib3","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannova","year":"2022","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.eclinm.2023.102059_bib4","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group","volume":"281","author":"Cooper","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102059_bib5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bjc.2017.21","article-title":"Long-term results and recurrence patterns from SCOPE-1: a phase II\/III randomised trial of definitive chemoradiotherapy\u00a0+\/- cetuximab in oesophageal cancer","volume":"116","author":"Crosby","year":"2017","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102059_bib6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(13)70136-0","article-title":"Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial","volume":"14","author":"Crosby","year":"2013","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102059_bib7","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/cncr.26586","article-title":"Failure patterns in patients with esophageal cancer treated with definitive chemoradiation","volume":"118","author":"Welsh","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102059_bib8","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ijrobp.2008.04.062","article-title":"Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy","volume":"73","author":"Button","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102059_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/clon.2003.0212","article-title":"Relapse patterns after chemo-radiation for carcinoma of the oesophagus","volume":"15","author":"Denham","year":"2003","journal-title":"Clin Oncol"},{"issue":"24","key":"10.1016\/j.eclinm.2023.102059_bib10","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","article-title":"Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus","volume":"326","author":"Herskovic","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.eclinm.2023.102059_bib11","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102059_bib12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/annonc\/mdt589","article-title":"A\u00a0comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients","volume":"25","author":"Honing","year":"2014","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102059_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/dote.12215","article-title":"Definitive chemoradiation for patients with inoperable and\/or unresectable esophageal cancer: locoregional recurrence pattern","volume":"28","author":"Versteijne","year":"2015","journal-title":"Dis Esophagus"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102059_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3727\/096504016X14537290676865","article-title":"Clinical outcome in definitive concurrent chemoradiation with weekly paclitaxel and carboplatin for locally advanced esophageal and junctional cancer","volume":"23","author":"Noronha","year":"2016","journal-title":"Oncol Res"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102059_bib15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2967\/jnumed.110.085803","article-title":"18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial","volume":"52","author":"zum Buschenfelde","year":"2011","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102059_bib16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1470-2045(07)70244-9","article-title":"PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial","volume":"8","author":"Lordick","year":"2007","journal-title":"Lancet Oncol"},{"issue":"29","key":"10.1016\/j.eclinm.2023.102059_bib17","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1200\/JCO.2006.06.7801","article-title":"Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction","volume":"24","author":"Ott","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102059_bib18","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO.2001.19.12.3058","article-title":"Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging","volume":"19","author":"Weber","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.eclinm.2023.102059_bib19","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.20.03611","article-title":"Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (alliance) trial","volume":"39","author":"Goodman","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102059_bib20","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/j.clon.2022.03.019","volume":"34","author":"Bridges","year":"2022","journal-title":"Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102059_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fonc.2017.00083","article-title":"Data-based radiation oncology: design of clinical trials in the toxicity biomarkers era","volume":"7","author":"Azria","year":"2017","journal-title":"Front Oncol"},{"issue":"25","key":"10.1016\/j.eclinm.2023.102059_bib22","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3, Supplement","key":"10.1016\/j.eclinm.2023.102059_bib23","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.ijrobp.2021.07.045","article-title":"Exclusive chemoradiotherapy with or without radiation dose escalation in esophageal cancer: multicenter phase 2\/3 randomized trial CONCORDE (PRODIGE-26)","volume":"111","author":"Crehange","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102059_bib24","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaoncol.2017.1598","article-title":"Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial","volume":"3","author":"Suntharalingam","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102059_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1470-2045(21)00718-X","article-title":"Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology\/RTOG 1010): a multicentre, randomised, phase 3 trial","volume":"23","author":"Safran","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102059_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"issue":"16","key":"10.1016\/j.eclinm.2023.102059_bib27","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.eclinm.2023.102059_bib28","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102059_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2022.07.027","article-title":"PET-directed combined modality therapy for gastroesophageal junction cancer: results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK)","volume":"175","author":"Lorenzen","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2023.102059_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211065153","article-title":"PET\/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study","volume":"13","author":"Obermannova","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102059_bib31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.annonc.2019.10.019","volume":"31","author":"Barbour","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102059_bib32","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1007\/s00259-008-0851-9","article-title":"Prediction of tumour response by FDG-PET in patients with adenocarcinomas of the oesophagogastric junction","volume":"35","author":"Bollschweiler","year":"2008","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102059_bib33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/SLA.0000000000005619","article-title":"An international cohort study of prognosis associated with pathologically complete response following neoadjuvant chemotherapy versus chemoradiotherapy of surgical treated esophageal adenocarcinoma","volume":"276","author":"Cools-Lartigue","year":"2022","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102059_bib34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jtho.2018.10.152","article-title":"Positron-emission tomography scan-directed chemoradiation for esophageal squamous cell carcinoma: No benefit for a change in chemotherapy in positron-emission tomography nonresponders","volume":"14","author":"Greally","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102059_bib35","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/cncr.26591","article-title":"Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer","volume":"118","author":"Ilson","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2023.102059_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.05.020","article-title":"Oxaliplatin\/capecitabine or carboplatin\/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): long-term results of a randomised controlled trial","volume":"153","author":"Mukherjee","year":"2021","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102059_bib37","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1007\/s00259-021-05390-4","article-title":"New PET technologies - embracing progress and pushing the limits","volume":"48","author":"Aide","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023002365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023002365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:22:09Z","timestamp":1762899729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023002365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":37,"alternative-id":["S2589537023002365"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102059","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102059"}}